Abstract:Pulmonary hypertension (PHT) is an emerging common complication of hereditary hemolytic anemias. It has been mechanistically and epidemiologically linked to intravascular hemolysis and decreased nitric oxide (NO) bioavailability. While this complication has been described in approximately 30% of adult patients with sickle cell disease and thalassemia, the prevalence of PHT in patients with paroxysmal nocturnal hemoglobinuria (PNH), an acquired disease with the highest levels of intravascular hemolysis observed, has never been determined. PNH patients frequently have symptoms consistent with both hemolysis and PHT including severe fatigue and dyspnea on exertion. Therefore, we examined for the presence of PHT in PNH and explored potential mechanisms associated with its development by measuring the ability of plasma to instantaneously consume NO using ozone-based chemiluminescence. Doppler echocardiography was performed in 24 hemolytic PNH patients to estimate pulmonary artery systolic pressures. Systolic PHT was defined by a tricuspid regurgitant jet velocity (TRV) ≥ 2.5m/s at rest. Eleven (46%) patients had elevated pulmonary artery systolic pressures (mean TRV 2.7m/s ± 0.08) and one (4%) had severely elevated pressures (TRV 3.5m/s). Plasma from PNH patients (n=28) consumed 32.26 ± 8.74μM NO while normal subjects (n=9) consumed 2.42 ± 0.77μM NO (p=0.03). LDH levels correlated with NO consumption (p<0.001). Of the 24 patients evaluated for pulmonary pressure, there was no significant correlation between PHT and severity of NO consumption. In a separate analysis, 4 patients treated with eculizumab in the initial pilot study demonstrated a lower NO consumption at 7.34 ± 5.68μM NO at a median of 3.1 (2.3 – 3.1) years after starting eculizumab. Interestingly, 8 of 12 patients not on primary warfarin prophylaxis had PHT whereas only 3 of 12 patients on warfarin had PHT (p=0.04). In addition, warfarin therapy correlated inversely with TRV (R=−0.54; P=0.007). In summary, 1) PHT appears to be extremely common in patients with PNH, adding an additional hemolytic anemia to the growing list of human hemolytic diseases associated with PHT, 2) patients with PNH demonstrate high levels of NO consumption that are highly correlated to intravascular hemolysis (LDH) in these patients, 3) warfarin therapy is associated with lower rates of pulmonary hypertension supporting a strong rationale for primary prophylaxis with warfarin, and 4) eculizumab therapy is associated with reduced levels of NO consumption. Since NO consumption is associated with increased risk of thrombosis, it is possible that NO consumption contributes to thrombosis in PNH patients with PHT. Thus, inhibition of intravascular hemolysis and subsequent NO consumption may be a reasonable approach to reducing thrombotic risk and potentially the incidence of PHT in PNH. Additional studies are required to determine the contributions of chronic pulmonary thromboembolic disease, intravascular hemolysis and reduced NO bioavailability to the pathogenesis of pulmonary hypertension in PNH.

Hemodynamic response to inhaled nitric oxide in patients with pulmonary hypertension and chronic kidney disease: A retrospective cohort study

Inhaled Nitric Oxide in Preterm and Term Neonates with Hypoxemic Respiratory Failure and Persistent Pulmonary Hypertension

Nitric Oxide in the Evaluation of Congenital Heart Disease with Pulmonary Hypertension: Factors Related to Nitric Oxide Response

Pulmonary vasodilators in patients with advanced chronic kidney disease and pre-capillary pulmonary hypertension-A case series

Reply to Coutrot Et Al.: is Nitric Oxide Nephro- or Cardioprotective?

Safety of inhaled nitric oxide withdrawal in severe chronic pulmonary hypertension

The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension

Use of inhaled nitric oxide in submassive intermediate-risk pulmonary embolism: a single-centre experience

New Modalities for the Administration of Inhaled Nitric Oxide in Intensive Care Units After Cardiac Surgery or for Neonatal Indications: A Prospective Observational Study

Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes

Association of Cardiopulmonary Hemodynamics and Outcomes in Pulmonary Hypertension Following Kidney Transplant: A Multicenter Retrospective Cohort Study

Coronary and Systemic Vasodilator Responsiveness of Patients Receiving Conventional Intermittent or Nocturnal Hemodialysis

Nitroprusside Combined with Leg Raise at the Time of Right Heart Catheterization to Differentiate Precapillary from Other Hemodynamic Forms of Pulmonary Hypertension: A Single-Center Pilot Study

Nitric Oxide Consumption and Pulmonary Hypertension in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Inhaled nitric oxide in the treatment of moderate persistent pulmonary hypertension of the newborn: a randomized controlled, multicenter trial

Effect of Acute Vasodilator Testing Using Oxygen in Pulmonary Hypertension Due to Left Heart Disease

Inhalation of Nitric Oxide in Congenital Heart Defects Associated with Pulmonary Hypertension

Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker

Inhibition of nitric oxide synthase unmasks vigorous vasoconstriction in established pulmonary arterial hypertension

Impact of inhaled nitric oxide therapy in patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation combined with Impella

Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension